MedWatch - The FDA Safety Information and Adverse Event Reporting Program
FDA notified healthcare professionals that, based on emerging information,
including preliminary reports from one of several long term National
Institutes of Health (NIH) prevention studies, the risk of cardiovascular
events may be increased in patients receiving Celebrex. FDA is analyzing all
available information from these studies to determine whether additional
regulatory action is needed.